Fedex Securities Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Letter of Offer for the attention of the Public Shareholders of Parmax Pharma Ltd ("Target Company").
M&A
● No Immediate Change
MEDIUM RISK
📅 Filed on BSE: 22 Jul 2026, 01:41 PM IST · BSE ID: 0002029e-4d85-45da-8dff-cddc5fa75672
View Original BSE Filing (PDF)
💡
In Simple Terms
The official document for new owners to buy up to 26.00% of Parmax Pharma shares from existing public shareholders is now public.
🤖 AI Summary
- Letter of Offer submitted for acquiring 23,46,250 equity shares of Parmax Pharma.
- Offer represents 26.00% of Parmax Pharma's Expanded Voting Share Capital.
- Acquirers are Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with ten PACs.
- Fedex Securities Private Limited is the Manager to the Open Offer.
- The Letter of Offer is for public shareholders of Parmax Pharma Limited.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Number of Equity Shares to be acquired in Open Offer
23,46,250
Percentage of Expanded Voting Share Capital
26.00%
Face value per Equity Share
₹ 10.00
🏢 How This Affects the Company
The open offer process creates a period of market activity specific to the acquisition of shares, which may involve certain procedural risks for participating shareholders.
👥 What This Means For Shareholders
✅
Action Required
Public shareholders of Parmax Pharma Limited should review the Letter of Offer to understand the terms and conditions if they wish to tender their shares in the open offer.
👤
Who Is Affected
Public shareholders holding equity shares of Parmax Pharma Limited are affected, as they have the option to tender their shares in the open offer for up to 26.00% of the company's expanded voting share capital.
🔍
Management Signal
The submission of the Letter of Offer indicates the Acquirers and associated Persons Acting in Concert (PACs) are progressing with the planned acquisition of a significant stake in Parmax Pharma.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Open offer schedule — check for dates of offer period commencement and closure.
Outcome of open offer — confirm total shares tendered and acquired by the Acquirers.
Any further regulatory filings by the Acquirers or Parmax Pharma regarding the acquisition.
MEDIUM RISK
The open offer involves multiple parties and regulatory steps, introducing execution risk for both Acquirers and tendering shareholders.
💡 Investor Takeaway
The Letter of Offer for the open offer to acquire up to 23,46,250 equity shares, representing 26.00% of Parmax Pharma's Expanded Voting Share Capital, has been submitted by the Acquirers to public shareholders, confirming the process is underway.
📅 Company Track Record
Previous filings indicated that new Acquirers planned to gain control of Parmax Pharma, intending to inject ₹19.28 Crore via a preferential issue. The draft Letter of Offer for this open offer to acquire 26.00% of equity shares was submitted on 2026-06-23, following a share purchase agreement and public announcement on 2026-06-09.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the purpose of the Letter of Offer for Parmax Pharma?
The Letter of Offer is being sent to public shareholders of Parmax Pharma Limited to provide details regarding the open offer by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with their PACs, to acquire shares.
How many shares are the Acquirers targeting in the open offer for Parmax Pharma?
The Acquirers are seeking to acquire up to 23,46,250 fully paid-up equity shares of Parmax Pharma Limited, which represents 26.00% of the Expanded Voting Share Capital.
Who are the Acquirers involved in the open offer for Parmax Pharma?
The Acquirers are Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with ten Persons Acting in Concert (PACs), including Dhairya Dhiren Shah and Hiren Pravin Doshi.
What is the face value of each equity share of Parmax Pharma in this open offer?
Each equity share of Parmax Pharma Limited has a face value of ₹ 10.00, as stated in the Letter of Offer.
Questions based on this BSE filing only. For information purposes.